West Pharmaceutical Services, Inc.

NYSE:WST

Medical - Instruments & Supplies

Healthcare
$404.02 +1.56%

+$5.04 today

Market cap
$28.14B
Beta
1.18
P/E (TTM)
43.6
EPS (TTM)
$7.54
Dividend yield
0.26%
52W Low $206.80High $336.82

Volume 0.59M

Average 0.85M

WST Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

West Pharmaceutical Services, Inc.NYSE: WST

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue grows in line with its trailing trend

Q2 FY2026 revenue of $872.3M rose 13.8% year over year, ahead of the +12.4% change in trailing-twelve-month revenue. Sequentially, it rose 3.2% from the prior quarter. Over 3 fiscal years it compounded at +2.1% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 12 analysts of $3.42B (+11.2%) for the fiscal year ending Dec 2026, a step up from the +6.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$872.3M+3.2% QoQ
Last fiscal yearDec 2025
$3.07B+6.3% YoY
LTMJun 2026
$3.33B+12.4% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.8%+2.8%-11.0 pp
1 year+6.3%+11.2%+5.0 pp
3-year CAGR+2.1%+8.3%+6.2 pp
5-year CAGR+7.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
3.07B USD
Year-over-year change
+6.3%
4-year CAGR
+2.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How WST compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +12.4% is the 2nd highest of 5, against a peer median of +7.8%.
  • Over three fiscal years its annual growth of +2.1% compares with a peer median of +4.7%.
WST Competitors
Revenue for WST and competitors
Company Period LTM YoY 3-year CAGR
ATRAptarGroup, Inc.LTM Jun 2026$3.93B USD+8.9%+4.4%
WSTWest Pharmaceutical Services, Inc.LTM Jun 2026$3.33B USD+12.4%+2.1%
ICUIICU Medical, Inc.LTM Jun 2026$2.16B USD-9.0%-0.7%
STVNStevanato Group S.p.A.LTM Jun 2026€1.22B EUR+6.7%+5.0%
BLFSBioLife Solutions, Inc.LTM Mar 2026$99.77M USD+40.9%+8.1%
Peer median (excluding WST) —+7.8%+4.7%

Competitors are the stored peer set for WST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.83B2.89B2.95B2.89B3.07B
Cost of Revenue1.66B1.75B1.82B1.89B1.97B
Gross Profit1.17B1.14B1.13B1B1.1B
Gross Margin41.5%39.5%38.4%34.6%35.9%
Research & Development52.8M58.5M68.4M69.1M74.3M
Selling, General & Admin361.9M316.9M353.4M338.5M393.1M
Operating Expenses414.7M375.4M421.8M407.6M485.9M
Depreciation & Amortization122.3M120.6M137.3M155.4M171.4M
EBITDA879.7M808.1M844.1M743.8M770.6M
EBITDA Margin31.1%28.0%28.6%25.7%25.1%
Operating Income758.7M763.5M710.9M594.6M617.4M
Operating Margin26.8%26.5%24.1%20.6%20.1%
Interest Income1M5.1M28M19.6M17.7M
Interest Expense8.5M7.6M8.8M2.9M600K
Other Income / Expenses10.3M(62.9M)4.8M5.6M(2.1M)
Income Before Tax769M700.6M715.7M600.2M615.3M
Pre-Tax Margin27.2%24.3%24.3%20.7%20.0%
Income Tax Expense107.2M114.7M122.3M107.5M121.6M
Net Income661.8M585.9M593.4M492.7M493.7M
Net Margin23.4%20.3%20.1%17.0%16.1%
EPS (Basic)8.907.887.996.756.83
EPS (Diluted)8.677.737.886.696.80
Weighted Avg Shares74.4M74.4M74.3M73M72.3M
Weighted Avg Shares (Diluted)76.3M75.8M75.3M73.7M72.7M

West Pharmaceutical Services, Inc.

NYSE:WST

Intrinsic Alpha fair value

Locked

Current Price

$404.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.